What is the Market's View on Allakos Inc (ALLK) Stock's Price and Volume Trends Monday?

The market has been down on Allakos Inc (ALLK) stock recently. ALLK gets a Bearish score from InvestorsObserver Stock Sentiment Indicator.

Allakos Inc has a Bearish sentiment reading. Find out what this means for you and get the rest of the rankings on ALLK!

See Full ALLK Report

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Recent trends are a good indicator of current market sentiments. In its most basic form, stocks that are trending up are desirable by investors while stocks currently falling must be unattractive. InvestorsObserver's Sentimental Indicator tracks both changes in price and volume to analyze the most recent trends. Typically an increase in volume indicates ongoing trends are getting stronger, while a decrease in volume usually signals an end to the current trend. Available options can also represent current sentiments for a given stock. Since investors are able to bet on future trends of stocks using options, we consider the ratio of calls to puts when analyzing market sentiments .

What's Happening With ALLK Stock Today?

Allakos Inc (ALLK) stock has fallen -6.87% while the S&P 500 has gained 1.01% as of 10:14 AM on Monday, Mar 18. ALLK is lower by -$0.09 from the previous closing price of $1.31 on volume of 84,209 shares. Over the past year the S&P 500 has gained 30.80% while ALLK is lower by -75.40%. ALLK lost -$2.14 per share in the over the last 12 months.

More About Allakos Inc

Allakos Inc is a clinical-stage company developing therapeutic antibodies that selectively target immunomodulatory receptors present on the surface of immune effector cells involved in allergic, inflammatory, and proliferative diseases. The company's lead program, AK002, an antibody that targets Siglec-8, an inhibitory receptor found on eosinophils and mast cells. In preclinical and clinical studies, AK002 has been shown to deplete eosinophils and inhibit mast cells. Click Here to get the full Stock Report for Allakos Inc stock.